All patients | Not referred for ICU admission | Referred for ICU admission | p-value | |
Patients | 140 | 91 (65) | 49 (35) | |
Demographics | ||||
Sex | 0.57 | |||
Male | 104 (74) | 69 (66) | 35 (34) | |
Female | 22 (61) | 14 (39) | ||
Age years | 65 (58–74) | 64 (58–74) | 67 (59–72) | 0.84 |
Performance status | <10−4 | |||
0–2 | 55 (39) | 20 (26) | 35 (64) | |
3–4 | 85 (61) | 71 (84) | 14 (16) | |
Modified CCI | 0.84 | |||
0 | 93 (66) | 61 (66) | 32 (34) | |
⩾1 | 47 (34) | 30 (64) | 17 (36) | |
Weight loss % | 11 (7–20) | 13 (7–20) | 9 (6–17) | 0.08 |
Cancer history | ||||
Time from cancer diagnosis months | 5.0 (1.0–15.4) | 6.3 (1.5–17.4) | 1.8 (0.7–8.8) | 0.01 |
Type of cancer | 0.10 | |||
Adenocarcinoma | 66 (47) | 45 (68) | 21 (32) | |
Squamous cell carcinoma | 23 (16) | 10 (43) | 13 (57) | |
Small cell carcinoma | 26 (19) | 17 (65) | 9 (35) | |
Other | 25 (18) | 19 (76) | 6 (24) | |
Metastasis at inclusion | 10−3 | |||
Yes | 119 (85) | 84 (71) | 35 (29) | |
No | 21 (15) | 7 (33) | 14 (67) | |
Cancer status | <10−4 | |||
Controlled disease | 18 (13) | 8 (44) | 10 (56) | |
Progression | 52 (37) | 46 (88) | 6 (12) | |
Unknown | 36 (26) | 21 (58) | 15 (42) | |
Not yet treated | 34 (24) | 16 (47) | 18 (53) | |
Current anticancer treatment | <10−4 | |||
None | 48 (34) | 46 (96) | 2 (4) | |
Awaiting treatment | 40 (29) | 19 (48) | 21 (53) | |
Treatment ongoing | 45 (32) | 24 (53) | 21 (47) | |
Therapeutic window | 7 (5) | 2 (29) | 5 (71) | |
Patient/family stated they refuse ICU admission | <10−4 | |||
Yes | 49 (35) | 44 (90) | 5 (10) | |
No | 91 (65) | 47 (52) | 44 (48) |
Data are presented as n, n (%) or median (interquartile range), unless otherwise stated. CCI: Charlson Comorbidity Index [19].